partners in EU, Canada & US
MOMENTUM will use Elekta’s Unity magnetic resonance radiation therapy (MR/RT) system MR-Linac, which integrates a state-of-the-art linear accelerator (to deliver radiation therapy) into a high-resolution MR device. The MR-Linac Unity is the first of its kind that allows clinicians to see and track difficult-to-visualize soft tissue anatomies in real-time during radiation treatment. The primary goal of the MOMENTUM Study is to create a linked clinical and technical data repository that will support optimization of Unity software and treatment paradigms and evaluate treatment outcomes in common cancer types.
Radiation therapy is essential for the treatment of many cancer types, but is also associated with severe side effects. By combining real time MR visualization with radiation therapy, the MR-linac aims to offer an optimal radiation treatment approach to improve patients’ survival, while also reducing damage to surrounding, healthy tissue. The MOMENTUM study will help to define how different types of tumours should be treated and identify which patients can benefit the most from this approach.
MOMENTUM is a cross-atlantic collaboration coordinated by UMC Utrecht, and involves partners from academia and industry in Europe, the United States and Canada. MOMENTUM involves seven world-leading oncology medical centres across Europe and North America in 2018 (two in the Netherlands, two in the United Kingdom, two in the United States and one in Canada).
Those who are interested, can download the MOMENTUM package, which includes the data dictionary, the standard operating procedures, and the clinical protocol.
Enabling unification of stakeholders
Lygature played an instrumental role in setting up the governance structure and drafting a consortium agreement that met the founding partners’ needs. Furthermore, Lygature utilizes its management capabilities to ensure that the project delivers optimal treatments for all patients. Activities include:
- Partnership management. Lygature plays a pivotal role in amalgamating the partnership, creating one coherent research consortium. As an independent enabler, Lygature focuses entirely on making the collaboration work for the benefit of all partners, ensuring valuable output for the development of this innovative medical solution for patients.
- Agreement support. Lygature provides support in translation of the project in clear contractual language and well-balanced rights and obligations of all partners. Lygature will monitor the continued adequacy of the agreement and guide required amendments based on the developments within the consortium.
- Data infrastructure expertise. Lygature provides the necessary expertise needed to set up data management plans and to develop standard operating procedures to ensure smooth operation within the project.
- Project management and monitoring. Lygature handles day-to-day operations of the MOMENTUM study, including drafting and assessing project activity reports and structuring actions. Lygature also provides the project with an ICT environment for file sharing and publication management.
MOMENTUM contributes to Lygature’s mission of accelerating the development of new medical solutions for patients. Lygature provides extensive management capabilities and expertise as a custodian of trust to move this multi-stakeholder research project forward.
Lygature together with
MOMENTUM study reaches 500-patient milestone
MOMENTUM, a study focused on tracking the outcomes of combining Magnetic Resonance (MR) and Radiation Therapy (RT) to treat common types of cancer, has successfully enrolled 500 patients – an impressive milestone to have reached in just over a year, across seven collaborating institutions in four countries.
MOMENTUM stands for Multiple Outcome Evaluation of Radiotherapy Using the MR-Linac – a machine that combines imaging (MR) and treatment (RT) to precisely locate and irradiate tumours. The study is observational and uses the data of enrolled patients to track the effectiveness and benefits of using the state-of-the art MR-Linac machine, ELEKTA Unity.
Each patient enrolled in the study is asked to give informed consent so that they know what is being done with their treatment data. In addition to their data being tracked and stored in the MOMENTUM database, the patients are also questioned on their quality of life. In time, all of this information will help to define how different types of tumours can and should be treated. It will also identify which patients benefit the most from the MR-Linac approach.
Read more here.
Program Manager Kristina Orrling interviewed on MOMENTUM
Focus, Elekta’s online magazine, interviews Kristina Orrling about MOMENTUM and how the study help accelerate the introduction of magnetic resonance radiation therapy (MR/RT) for cancer patients into clinical practice. Kristina says: “Bringing leading parties together, MOMENTUM is a unique opportunity to learn how to use the technology in the best possible way and for Elekta to understand how to enhance the product”.
Read the full interview here.
First patients being enrolled in MOMENTUM study in the USA
On April 30th, Medical College of Wisconsin (MCW) physicians and researchers from one of the most prominent Cancer Centers in the USA, the Froedtert & the Medical College of Wisconsin Clinical Cancer Center at Froedtert Hospital, announced the first patients have been treated and registered in the MOMENTUM database. From now on, they will collect data from patients on treatment with MR-guided radiotherapy, tumor control rates, quality of life and other outcomes.
The data to be collected in the MOMENTUM study there, and at the other participating centers in the Netherlands, UK, Canada, and USA, will be used to optimize Elekta’s Unity to ensure safe, fast, and ‘evidence-based’ introduction of magnetic resonance radiation therapy (MR/RT) into clinical practice. Sharing such pseudonymized patient data between centers at different continents can be a challenge. Lygature assisted the MR-linac Consortium in finding legal and contractual solutions to allow this, enabling the researchers to access a larger pool of data, accelerating robust evaluation of the clinical use of this novel tumor treatment.
Read more here.